Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice

被引:45
作者
Hsu, CX
Ross, BD
Chrisp, CE
Derrow, SZ
Charles, LG
Pienta, KJ
Greenberg, NM
Zeng, Z
Sanda, MG
机构
[1] Univ Michigan, Taubman Ctr 2916, Sch Med,Surg Serv,Ann Arbor Vet Adm Med Ctr, Dept Surg Urol,Unit Lab Anim Med & Med Urol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Taubman Ctr 2916, Sch Med,Surg Serv,Ann Arbor Vet Adm Med Ctr, Dept Radiol,Unit Lab Anim Med & Med Urol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Taubman Ctr 2916, Sch Med,Surg Serv,Ann Arbor Vet Adm Med Ctr, Dept Biol Chem,Unit Lab Anim Med & Med Urol, Ann Arbor, MI 48109 USA
[4] Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA
关键词
prostate cancer; transgenic mice; MRI; SV40-T antigen; tumor volume;
D O I
10.1016/S0022-5347(01)62603-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Human prostate cancer is variably lethal, shows heterogeneous progression, and exhibits a spectrum of histopathology. Traditional rodent models of prostate cancer lack these characteristics. An alternative, autochthonous model of prostate cancer consists of transgenic mice which develop prostate cancer due to prostatic expression of SV40 T antigen. Lethal progression of such cancers in individual mice has not been previously characterized. Studies were undertaken to characterize the longitudinal progression of prostate cancers in these transgenic mice. Methods: A prospective longitudinal cohort study was undertaken to characterize prostate cancer volume, progression, lethality, and histological heterogeneity in a transgenic mouse model of prostatic adenocarcinoma. Fifty-one transgenic mice were followed prospectively to determine the age at onset of palpable tumor and age at cancer-related death. Tumor volume was followed longitudinally by magnetic resonance imaging (MRI) in a subset of these mice and lethal cancers were evaluated by histopathology. Results: Primary tumors became palpable at 10-38 weeks of age. Palpable tumors always preceded lethal progression. Cancer death followed 2-9 weeks later, and age at cancer death varied from 24 to 39 weeks of age. The histopathological changes were heterogeneous. Primary tumors were detectable by MRI before they became detectable by palpation. MRI showed that, analogous to human prostate cancers, volume of early stage primary tumors did not necessarily predict age at cancer death. Conclusion: Prostate cancer in transgenic mice mimics heterogeneic tumor progression in human prostate cancer, providing a uniquely relevant pre-clinical model. Tumor detection by MRI and palpation are valid surrogate measures of tumor progression in this model.
引用
收藏
页码:1500 / 1505
页数:6
相关论文
共 31 条
[1]   INTRAVESICAL GROWTH OF MURINE BLADDER-TUMORS ASSESSED BY TRANSRECTAL ULTRASOUND [J].
ALEXANDER, AA ;
LIU, JB ;
MCCUE, P ;
GOMELLA, LG ;
ROSS, RP ;
LATTIME, EC .
JOURNAL OF UROLOGY, 1993, 150 (02) :525-528
[2]  
BOSLAND MC, 1992, J CELL BIOCHEM, P89
[3]   RODENT MODELS FOR TARGETED ONCOGENESIS OF THE PROSTATE-GLAND [J].
BUTTYAN, R ;
SLAWIN, K .
CANCER AND METASTASIS REVIEWS, 1993, 12 (01) :11-19
[4]   AN EMBRYONIC PATTERN OF EXPRESSION OF A HUMAN-FETAL GLOBIN GENE IN TRANSGENIC MICE [J].
CHADA, K ;
MAGRAM, J ;
COSTANTINI, F .
NATURE, 1986, 319 (6055) :685-689
[5]   MAGNETIC-RESONANCE-IMAGING FOR DETECTING AND TREATMENT MONITORING OF ORTHOTOPIC MURINE BLADDER-TUMOR IMPLANTS [J].
CHIN, J ;
KADHIM, S ;
GARCIA, B ;
KIM, YS ;
KARLIK, S .
JOURNAL OF UROLOGY, 1991, 145 (06) :1297-1301
[6]  
DODD JG, 1983, J BIOL CHEM, V258, P731
[7]  
Gingrich JR, 1996, CANCER RES, V56, P4096
[8]   PROSTATE-CANCER IN A TRANSGENIC MOUSE [J].
GREENBERG, NM ;
DEMAYO, F ;
FINEGOLD, MJ ;
MEDINA, D ;
TILLEY, WD ;
ASPINALL, JO ;
CUNHA, GR ;
DONJACOUR, AA ;
MATUSIK, RJ ;
ROSEN, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) :3439-3443
[9]   THE RAT PROBASIN GENE PROMOTER DIRECTS HORMONALLY AND DEVELOPMENTALLY-REGULATED EXPRESSION OF A HETEROLOGOUS GENE SPECIFICALLY TO THE PROSTATE IN TRANSGENIC MICE [J].
GREENBERG, NM ;
DEMAYO, FJ ;
SHEPPARD, PC ;
BARRIOS, R ;
LEBOVITZ, R ;
FINEGOLD, M ;
ANGELOPOULOU, R ;
DODD, JG ;
DUCKWORTH, ML ;
ROSEN, JM ;
MATUSIK, RJ .
MOLECULAR ENDOCRINOLOGY, 1994, 8 (02) :230-239
[10]  
ISAACS JT, 1983, CLIN ONCOLO, V2, P479